Table 1: Primary Clinical Areas of Focus for Studies Using Multicenter NICU Databases

Primary Clinical Focus Area / Count / Percent (%) / Citations
Respiratory Treatments & Outcomes / 67 / 19.53% / 1-66
Neurodevelopmental, Growth, or Language Outcomes / 45 / 13.12% / 67-111
Outcomes of VLBW/ELBW / 39 / 11.37% / 112-150
Encephalopathy / 24 / 7.00% / 151-174
Neonatal Infections / 18 / 5.25% / 175-192
Intestinal Disease / 15 / 4.37% / 193-207
Sepsis / 14 / 4.08% / 208-221
Antenatal Corticosteriod Treatment / 10 / 2.92% / 222-231
Retinopathy of Prematurity / 8 / 2.33% / 232-239
Hyperbilirubinemia / 8 / 2.33% / 240-247
Other / 95 / 27.70% / 248-343
Total / 343 / 100%

References

1. Escobar GJ, Gebretsadik T, Carroll K, Li SX, Walsh EM, Wu P, et al. Adherence to Immunoprophylaxis Regimens for Respiratory Syncytial Virus Infection in Insured and Medicaid Populations. Journal of the Pediatric Infectious Diseases Society. 2013;2(3):205-214.

2. Kuzniewicz M, Draper D, Escobar GJ. Incorporation of physiological trend and interaction effects in neonatal severity of illness scores: an experiment using a variant of the Richardson score. Intensive care medicine. 2007;33(9):1602-1608.

3. Wilson A, Gardner MN, Armstrong MA, Folck BF, Escobar GJ. Neonatal assisted ventilation: predictors, frequency, and duration in a mature managed care organization. Pediatrics. 2000;105(4):822-830.

4. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, et al. Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia. The Journal of pediatrics. 2004;144(6):799-803.

5. Escobar GJ, Ragins A, Li SX, Prager L, Masaquel AS, Kipnis P. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life. Archives of pediatrics & adolescent medicine. 2010;164(10):915-922.

6. Escobar GJ, Shaheen SM, Breed EM, Botas C, Greene JD, Yoshida CK, et al. Richardson score predicts short-term adverse respiratory outcomes in newborns≥ 34 weeks gestation. The Journal of pediatrics. 2004;145(6):754-760.

7. Lorch SA, Wade KC, Bakewell-Sachs S, Medoff-Cooper B, Escobar GJ, Silber JH. Racial differences in the use of respiratory medications in premature infants after discharge from the neonatal intensive care unit. The Journal of pediatrics. 2007;151(6):604-610. e601.

8. Anadkat J, Kuzniewicz M, Chaudhari B, Cole F, Hamvas A. Increased risk for respiratory distress among white, male, late preterm and term infants. Journal of Perinatology. 2012;32(10):780-785.

9. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. The Journal of pediatrics. 2005;146(4):469-473.

10. Ambalavanan N, Carlo WA, D'Angio CT, McDonald SA, Das A, Schendel D, et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics. 2009;123(4):1132-1141.

11. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116(6):1353-1360.

12. Kennedy KA, Stoll BJ, Ehrenkranz RA, Oh W, Wright LL, Stevenson DK, et al. Vitamin A to prevent bronchopulmonary dysplasia in very-low-birth-weight infants: has the dose been too low? The NICHD Neonatal Research Network. Early human development. 1997;49(1):19-31.

13. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. American journal of respiratory and critical care medicine. 2011;183(12):1715-1722.

14. Natarajan G, Pappas A, Shankaran S, Kendrick DE, Das A, Higgins RD, et al. Outcomes of extremely low birth weight infants with bronchopulmonary dysplasia: impact of the physiologic definition. Early human development. 2012;88(7):509-515.

15. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. The Journal of pediatrics. 2005;147(6):786-790.

16. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004;114(5):1305-1311.

17. Ambalavanan N, Walsh M, Bobashev G, Das A, Levine B, Carlo WA, et al. Intercenter differences in bronchopulmonary dysplasia or death among very low birth weight infants. Pediatrics. 2011;127(1):e106-116.

18. Fernandez E, Watterberg KL, Faix RG, Yoder BA, Walsh MC, Lacy CB, et al. Incidence, Management, and Outcomes of Cardiovascular Insufficiency in Critically Ill Term and Late Preterm Newborn Infants. American journal of perinatology. 2014.

19. Leitch CA, Ahlrichs J, Karn C, Denne SC. Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. Pediatr Res. 1999;46(1):109-113.

20. Finer NN, Carlo WA, Duara S, Fanaroff AA, Donovan EF, Wright LL, et al. Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial. Pediatrics. 2004;114(3):651-657.

21. Vaucher YE, Peralta-Carcelen M, Finer NN, Carlo WA, Gantz MG, Walsh MC, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med. 2012;367(26):2495-2504.

22. Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998;338(16):1112-1118.

23. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 2001;344(2):95-101.

24. Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, et al. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. The Journal of pediatrics. 2014;164(1):34-39.e32.

25. LeVan JM, Wyckoff MH, Ahn C, Heyne R, Sanchez PJ, Chalak L, et al. Change in care among nonenrolled patients during and after a randomized trial. Pediatrics. 2013;132(4):e960-970.

26. Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, et al. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics. 2004;113(3 Pt 1):559-564.

27. Konduri GG, Vohr B, Robertson C, Sokol GM, Solimano A, Singer J, et al. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. The Journal of pediatrics. 2007;150(3):235-240, 240.e231.

28. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336(9):597-604.

29. Sokol GM, Fineberg NS, Wright LL, Ehrenkranz RA. Changes in arterial oxygen tension when weaning neonates from inhaled nitric oxide. Pediatric pulmonology. 2001;32(1):14-19.

30. Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, et al. Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. Journal of perinatology : official journal of the California Perinatal Association. 2007;27(6):347-352.

31. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353(1):13-22.

32. Konduri GG, Sokol GM, Van Meurs KP, Singer J, Ambalavanan N, Lee T, et al. Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term/late preterm neonates with moderate hypoxic respiratory failure. Journal of perinatology : official journal of the California Perinatal Association. 2013;33(12):944-949.

33. Laptook AR, Salhab W, Allen J, Saha S, Walsh M. Pulse oximetry in very low birth weight infants: can oxygen saturation be maintained in the desired range? Journal of perinatology : official journal of the California Perinatal Association. 2006;26(6):337-341.

34. Truog WE, Nelin LD, Das A, Kendrick DE, Bell EF, Carlo WA, et al. Inhaled nitric oxide usage in preterm infants in the NICHD neonatal research network: inter-site variation and propensity evaluation. Journal of perinatology : official journal of the California Perinatal Association. 2014.

35. Walsh MC, Morris BH, Wrage LA, Vohr BR, Poole WK, Tyson JE, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. The Journal of pediatrics. 2005;146(6):798-804.

36. Wang K, Difiore JM, Martin RJ, Rosen CL, Hibbs AM. Markers for severity of illness associated with decreased snoring in toddlers born ELGA. Acta paediatrica (Oslo, Norway : 1992). 2013;102(1):e39-43.

37. Chock VY, Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Kendrick DE, et al. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. American journal of perinatology. 2009;26(4):317-322.

38. Walsh M, Laptook A, Kazzi SN, Engle WA, Yao Q, Rasmussen M, et al. A cluster-randomized trial of benchmarking and multimodal quality improvement to improve rates of survival free of bronchopulmonary dysplasia for infants with birth weights of less than 1250 grams. Pediatrics. 2007;119(5):876-890.

39. Thomas CW, Meinzen-Derr J, Hoath SB, Narendran V. Neurodevelopmental outcomes of extremely low birth weight infants ventilated with continuous positive airway pressure vs. mechanical ventilation. Indian journal of pediatrics. 2012;79(2):218-223.

40. Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362(21):1970-1979.

41. Di Fiore JM, Walsh M, Wrage L, Rich W, Finer N, Carlo WA, et al. Low oxygen saturation target range is associated with increased incidence of intermittent hypoxemia. The Journal of pediatrics. 2012;161(6):1047-1052.

42. St John EB, Carlo WA. Respiratory distress syndrome in VLBW infants: changes in management and outcomes observed by the NICHD Neonatal Research Network. Seminars in perinatology. 2003;27(4):288-292.

43. Ambalavanan N, Van Meurs KP, Perritt R, Carlo WA, Ehrenkranz RA, Stevenson DK, et al. Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure. Journal of perinatology : official journal of the California Perinatal Association. 2008;28(6):420-426.

44. Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. The Members of the National Institute of Child Health and Human Development Neonatal Research Network. Pediatrics. 1993;92(2):191-196.

45. Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. The Journal of pediatrics. 1993;123(5):757-766.

46. DeMauro SB, D'Agostino JA, Bann C, Bernbaum J, Gerdes M, Bell EF, et al. Developmental outcomes of very preterm infants with tracheostomies. The Journal of pediatrics. 2014;164(6):1303-1310.e1302.

47. Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, et al. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. The Journal of pediatrics. 2002;141(3):370-374.

48. Bhandari V, Finer NN, Ehrenkranz RA, Saha S, Das A, Walsh MC, et al. Synchronized nasal intermittent positive-pressure ventilation and neonatal outcomes. Pediatrics. 2009;124(2):517-526.

49. Dunn MS, Kaempf J, de Klerk A, de Klerk R, Reilly M, Howard D, et al. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics. 2011;128(5):e1069-1076.

50. Hentschel J, Berger TM, Tschopp A, Muller M, Adams M, Bucher HU. Population-based study of bronchopulmonary dysplasia in very low birth weight infants in Switzerland. Eur J Pediatr. 2005;164(5):292-297.

51. Mandy G, Malkar M, Welty SE, Brown R, Shepherd E, Gardner W, et al. Tracheostomy placement in infants with bronchopulmonary dysplasia: safety and outcomes. Pediatric pulmonology. 2013;48(3):245-249.

52. Payne NR, LaCorte M, Karna P, Chen S, Finkelstein M, Goldsmith JP, et al. Reduction of bronchopulmonary dysplasia after participation in the Breathsavers Group of the Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. Pediatrics. 2006;118 Suppl 2:S73-77.

53. Pinheiro JM, Boynton S, Furdon SA, Dugan R, Reu-Donlon C. Use of chemical warming packs during delivery room resuscitation is associated with decreased rates of hypothermia in very low-birth-weight neonates. Advances in neonatal care : official journal of the National Association of Neonatal Nurses. 2011;11(5):357-362.

54. Group TVONSS. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics. 2001;108(3):741-748.

55. Kirchner L, Weninger M, Unterasinger L, Birnbacher R, Hayde M, Krepler R, et al. Is the use of early nasal CPAP associated with lower rates of chronic lung disease and retinopathy of prematurity? Nine years of experience with the Vermont Oxford Neonatal Network. Journal of perinatal medicine. 2005;33(1):60-66.

56. Rudiger M, Ifflander S, Reichert J, Batzel C, Reiter G, Wauer RR. Which information will be given to parents of preterm infants--a comparison of estimates and local data. Journal of perinatal medicine. 2007;35(5):436-442.

57. Klebermass-Schrehof K, Wald M, Schwindt J, Grill A, Prusa AR, Haiden N, et al. Less invasive surfactant administration in extremely preterm infants: impact on mortality and morbidity. Neonatology. 2013;103(4):252-258.

58. Payne NR, Finkelstein MJ, Liu M, Kaempf JW, Sharek PJ, Olsen S. NICU practices and outcomes associated with 9 years of quality improvement collaboratives. Pediatrics. 2010;125(3):437-446.

59. Horbar JD, Carpenter JH, Buzas J, Soll RF, Suresh G, Bracken MB, et al. Collaborative quality improvement to promote evidence based surfactant for preterm infants: a cluster randomised trial. BMJ (Clinical research ed). 2004;329(7473):1004.

60. Horbar JD, Carpenter JH, Buzas J, Soll RF, Suresh G, Bracken MB, et al. Timing of initial surfactant treatment for infants 23 to 29 weeks' gestation: is routine practice evidence based? Pediatrics. 2004;113(6):1593-1602.

61. Malkar MB, Gardner WP, Mandy GT, Stenger MR, Nelin LD, Shepherd EG, et al. Respiratory severity score on day of life 30 is predictive of mortality and the length of mechanical ventilation in premature infants with protracted ventilation. Pediatric pulmonology. 2014.

62. Vermont-Oxford Neonatal Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics. 1996;97(1):1-6.

63. Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. Jama. 2003;289(9):1124-1129.